肺癌
劈理(地质)
癌症研究
细胞
化学
拓扑异构酶
突变
细胞生物学
磷酸二酯酶
突变
表皮生长因子受体抑制剂
生物
PTEN公司
癌细胞
抗药性
细胞培养
细胞生长
分子生物学
癌症
细胞周期
顺铂
药理学
酶
作者
Mathéa Géraud,Rémi Gence,Anne Casanova,Estelle Clermont,Simona Salimbeni,Nesibe Özsu,Maïna Vienne,Célia Delahaye,Elodie Borrull,Amélie Lusque,Mathilde Morisseau,Thomas Filleron,Delphine Pagan,Camille Taha,Agnese Cristini,Julien Mazières,Olivier Calvayrac,Gilles Favre,Anne Pradines,Olivier Sordet
出处
期刊:Science Advances
[American Association for the Advancement of Science]
日期:2026-09-23
卷期号:12 (39): eaeh9099-eaeh9099
标识
DOI:10.1126/sciadv.aeh9099
摘要
Resistance to targeted cancer therapies often arises from drug-tolerant cells, which survive treatment by entering a nonproliferative state. Over time, these cells can acquire mutations that contribute to cell reproliferation, but how nonproliferating drug-tolerant cells accumulate these mutations remains unclear. Here, we show that EGFR inhibition in EGFR -mutated lung cancer transiently down-regulates tyrosyl-DNA phosphodiesterase 1 (TDP1), a repair enzyme that resolves abortive topoisomerase I cleavage complexes (TOP1ccs). In drug-tolerant cells, elevated reactive oxygen species promote TOP1cc trapping, while TDP1 down-regulation impairs their repair, driving TOP1cc accumulation, resistance mutation acquisition, and cell reproliferation. We further find that TDP1 expression is absent in ∼25% of EGFR -mutated lung cancers. In TDP1-deficient cells, combining EGFR inhibition with a sublethal concentration of topotecan, which further increases TOP1ccs, abolishes cell reproliferation. Together, these findings establish persistent TOP1cc accumulation as a driver of therapy-induced mutagenesis linking drug tolerance to adaptive resistance and reveal TDP1 loss as a targetable vulnerability in EGFR-mutated lung cancers.
科研通智能强力驱动
Strongly Powered by AbleSci AI